Sophie Shen

Patient Safety Epidemiology
Bristol Myers Squibb, United States

Disclosure information not submitted.

Presentation(s):

• 4A-05 - Post-marketing Safety Surveillance of Cardiovascular Risk Among Individuals Using Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy: A Retrospective Cohort Study

  Monday, August 25, 2025
  5:15 PM - 5:30 PM ET